Drug or technology
6 developments in the corpus
Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
Latest
Everything in the corpus, newest first.
APR 17, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
FDA supplemental approval for valproic acid labeling change; no clinical trial data reported in this regulatory action record.
APR 8, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
FDA supplemental approval for a labeling change to valproic acid; does not report clinical trial data or efficacy evidence.
MAR 31, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
FDA supplemental approval of labeling for valproic acid syrup; this is a regulatory action record, not a clinical study, and does not contain efficacy or safety trial data.
MAR 31, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
This is an FDA supplemental approval action for valproic acid labeling; it documents a regulatory decision, not clinical trial evidence or efficacy data.
MAR 31, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
FDA supplemental approval for valproic acid labeling change; regulatory action only, no clinical trial data or efficacy evidence provided.
MAR 31, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
FDA supplemental approval of labeling for Stavzor (valproic acid); no clinical trial data or efficacy claims are presented in this regulatory action record.